<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102508">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872260</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011X2107</org_study_id>
    <nct_id>NCT01872260</nct_id>
  </id_info>
  <brief_title>Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer</brief_title>
  <official_title>A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to inform the future clinical development of the two
      investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719
      (PI3K-alpha inhibitor).

      This is a multi-center, open-label Phase Ib/II study. The Phase Ib portion of the study is a
      dose escalation to estimate the MTD and/or RP2D for three regimens: two double combinations,
      LEE011 with letrozole and BYL719 with letrozole, followed by the triple combination of
      LEE011 + BYL719 with letrozole.

      The  Phase Ib will be followed by a randomized Phase II study to assess the preliminary
      anti-tumor activity of the two double combination regimens (LEE011+letrozole and
      BYL719+letrozole) versus the triple combination (LEE011+BYL719 with letrozole) and to
      further evaluate their safety in patients with ER+/HER2- locally advanced or metastatic
      breast cancer.

      Approximately 300 adult women with ER+/HER2- locally advanced or metastatic breast cancer
      will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the combination of LEE011 (CDK4/6i) and BYL719 (PI3K-alpha-i)
      with letrozole in patients with ER+/HER2- breast cancer (BC).  In Phase Ib there are three
      dose escalation cohorts that will enroll sequentially.  Arm 1 is the escalation of the
      double combination LEE011 + letrozole; Arm 2 is the dose escalation of the double
      combination of BYL719 + letrozole.  The two double combinations will be followed by Arm 3
      the dose escalation of the triple combination of LEE011 + BYL719  with letrozole.  The three
      dose escalation cohorts will enroll patients with ER+/HER2- BC with any number of prior
      lines of endocrine therapy with up to one prior cytotoxic regimen in the metastatic or
      locally advanced setting. Pre- and post-treatment tumor biopsies are required in the three
      dose escalation cohorts.  Once the RP2D/MTD of each double regimen is identified, dose
      expansion cohorts of each of these two combinations will open and will enroll in the
      first-line setting to confirm the doses selected in each double combination; archival tumor
      tissue is required in these cohorts, although pre- and post-biopsies in these expansion
      cohorts are optional.

      Once the dose is identified for the triple combination, the randomized, three-arm Phase II
      portion of the study will commence enrollment.  This part of the trial will enroll in the
      first line setting in patients with ER+/HER2- BC and will randomize patients in a 1:1:1
      ratio to either double regimen (LEE011+letrozole or BYL719 +letrozole) or the triple
      combination of LEE011+BYL719 with letrozole.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of Dose limiting toxicities (DLTs) - Phase lb only</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS) - Phase ll only</measure>
    <time_frame>Average 17 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS as per RECIST v1.1 (by local investigator assessment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of LEE011 in combination with letrozole, BYL719 in combination with letrozole, and the triple combination of LEE011 +BYL719 with letrozole</measure>
    <time_frame>Average 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse Events (AEs), serious AEs (SAEs), changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration-time profiles of LEE011, BYL719 and letrozole</measure>
    <time_frame>Average 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterize the PK profiles of LEE011, BYL719, and letrozole when used in combination as well as to evaluate any other clinically significant metabolites that may be identified.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Average 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>ORR is defined as the proportion of patients with a best overall response of complete response or partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Average 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>DOR is calculated as the time from the date of first documented response (complete response (CR) or partial response (PR)) to the first documented date of progression or death due to underlying cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Average 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - Phase ll only</measure>
    <time_frame>Average 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS is defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last known date patient alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameters, including but not limited to AUCtau, Cmin, Cmax, Tmax, accumulation ratio (Racc)</measure>
    <time_frame>Average 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To characterize the PK profiles of LEE011, BYL719, and letrozole when used in combination as well as to evaluate any other clinically significant metabolites that may be identified.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>LEE011 + letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating), letrozole - 2.5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BYL719 + letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL719 - daily (dose escalating), letrozole - 2.5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEE011 + BYL719 + letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEE011 - 28 day cycles (21 days followed by a 7 day break -dose escalating), BYL719 - daily (dose escalating), letrozole 2.5 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>LEE011 - 28 day cycles (21 days followed by a 7 day break)</description>
    <arm_group_label>LEE011 + letrozole</arm_group_label>
    <arm_group_label>LEE011 + BYL719 + letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole 2.5 mg/day</description>
    <arm_group_label>LEE011 + letrozole</arm_group_label>
    <arm_group_label>BYL719 + letrozole</arm_group_label>
    <arm_group_label>LEE011 + BYL719 + letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYL719</intervention_name>
    <description>Daily</description>
    <arm_group_label>BYL719 + letrozole</arm_group_label>
    <arm_group_label>LEE011 + BYL719 + letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal, Estrogen-receptor positive breast cancer

          -  Phase Ib dose escalation only: Any number of prior lines of endocrine therapy is
             allowed with the exception of cytotoxic therapy which is limited to one prior line
             administered in the metastatic or locally advanced setting.

          -  Phase Ib dose expansion in Arms 1 and 2 and Phase II: No prior systemic treatment in
             the metastatic setting.

        Exclusion Criteria:

          -  HER2-overexpression in the patient's tumor tissue

          -  Patients with active CNS or other brain metastases

          -  Major surgery within 2 weeks

          -  Acute or chronic pancreatitis

          -  Bilateral diffuse lymphangitic carcinomatosis

          -  Another malignancy within 3 years

          -  Receiving hormone replacement therapy that cannot be discontinued

          -  Impaired cardiac function

          -  Patients with clinically manifest diabetes mellitus (treated and/or clinical signs or
             with fasting glucose ≥ 140 mg/dL / 7.8 mmol/L), history of gestational diabetes
             mellitus or documented steroid-induced diabetes mellitus.

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Highlands Oncology Group Dept of Highlands Oncology Grp</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Nickel</last_name>
      <phone>+1 479 872 8130</phone>
      <email>anickel@hogonc.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Thaddeus Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center SC-5</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virginia Naessig</last_name>
      <phone>310-248-6733</phone>
      <email>Virginia.naaessig@cshs.org</email>
    </contact>
    <investigator>
      <last_name>William Audeh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego, Moores Cancer Ctr Dept. of Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deborah Miller</last_name>
      <phone>858-822-5352</phone>
      <email>ddmiller@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Teresa Helsten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Onc Dept</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Fiermonte</last_name>
      <phone>415-514-6245</phone>
      <email>fiermontep@cc.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela Munster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute H. Lee Moffitt SC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sumin Hassani</last_name>
      <phone>813-745-1807</phone>
      <email>simin.hassani@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Roohi Ismail-Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Goshen Center for Cancer Dept of Onc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracy Thorne</last_name>
      <phone>574-364-2649</phone>
      <email>tthorne@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Bruetman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center Univ Kansas 2</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Ward</last_name>
      <phone>913-945-5792</phone>
      <email>Jward3@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Qamar J. Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital SC-5</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Clegg</last_name>
      <email>sclegg@partners.org</email>
    </contact>
    <investigator>
      <last_name>Dejan Juric</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center Dept of Onc</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Chen</last_name>
      <phone>603-650-6425</phone>
    </contact>
    <investigator>
      <last_name>Peter Kaufman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Dept of Oncology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katie Krier</last_name>
      <phone>513-584-0429</phone>
      <email>krierci@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>John Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve SC</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Calabro</last_name>
      <phone>216-844-4722</phone>
      <email>barbara.calabro@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Paula Silverman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Research Dept of Oncology</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI SC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Carroll</last_name>
      <phone>615-329-7432</phone>
      <email>danielle.carroll@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Erika P Hamillton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center Vanderbilt - Thompson Ln</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jamica K Quarles</last_name>
      <phone>615-936-1164</phone>
      <email>Jamica.p.quarles@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Ingrid Mayer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. Texas Oncology - Sammons</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taqi Mohammad</last_name>
      <phone>+1 214 370 1915</phone>
      <email>taqi.mohammad@mckesson.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Roberto Becerra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital / Methodist Cancer Center Dept of Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brianne Martin</last_name>
      <phone>713-441-6011</phone>
      <email>bmartin@tmhs.org</email>
    </contact>
    <investigator>
      <last_name>Angel Rodriguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center / UT Health Science Center Dept of Onc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cody Stubblefield</last_name>
      <phone>210-450-1789</phone>
      <email>stubblefielc@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Anand B Karnad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties Dept of Onc</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth McGuire-Robinson</last_name>
      <phone>253-428-8752</phone>
      <email>bmcguire@nwmsonline.com</email>
    </contact>
    <investigator>
      <last_name>Sibel Blau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6005</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>May 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>estrogen-receptor positive</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
